Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 120 for:    Anti-Bacterial | CYCLOSERINE OR SEROMYCIN

Cycloserine rTMS Plasticity Augmentation in Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03511599
Recruitment Status : Recruiting
First Posted : April 30, 2018
Last Update Posted : September 14, 2018
Sponsor:
Information provided by (Responsible Party):
University of Calgary

Brief Summary:
Transcranial magnetic stimulation (rTMS) is an investigational and therapeutic modality that impacts the connection strength between neurons by delivering patterned energy. In response to this patterned energy neurons fire and adapt by changing their connection strengths. This change in connection strengths is believed to be the underlying mechanism whereby this intervention has therapeutic benefit for this intervention in conditions such as depression. The purpose of this study is to test a means of enhancing the effect of rTMS using a medication (cycloserine) that has been shown to augment and stabilize activity dependent neuronal changes. The investigators wish to use the motor system, where the associated muscle response to brain stimulation can be measured, to probe activity dependent changes in connection strength between neurons.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: Cycloserine Device: Transcranial Magnetic Stimulation Drug: Placebo Oral Tablet Phase 1

Detailed Description:

This randomized, placebo-controlled, crossover trial will enroll 12 participants with Major Depressive Disorder. In one arm of the study, participants will randomly receive either 100mg of d-cycloserine (DCS, an antibiotic) or a placebo capsule, and participants will receive the other intervention one week later.

  1. We will recruit 12 participants aged 18-60 through community advertisement, carefully screened for exclusion factors related to rTMS and DCS.
  2. After screening, participants will come to the lab for a semi-structured interview involving the MINI-International Neuropsychiatric Interview for confirmation of the diagnosis of depression, and the absence of substance use disorders, absence of psychosis, and absence of bipolar disorder. The severity of their depressive symptoms will be quantified with the semi-structured clinical instrument Hamilton Depression Rating Scale, and participants will be retained in the study if their score is ≥15, indicating moderate severity. Finally, the antidepressant treatment history will be collected using the Antidepressant Treatment History Form.
  3. Eligible participants will be randomly assigned by random number sequence with allocation concealment to one of two first arms of the crossover study: a) placebo-DCS 100mg and b) DCS 100mg-placebo.
  4. Participants will complete the QIDS-SR (Quick Inventory of Depressive Symptoms-Self Report), the MDQ (Mood Disorders Questionnaire), the BAI (Beck Anxiety Inventory), and the STAI (State Trait Anxiety Inventory). Participants will report their perception of physical symptoms (potential side effects) in the 7 days before participating in the study taking the randomized capsule (Toronto Side Effects Scale - 1 Week).
  5. Participants will take their blinded capsule at least 30 minutes prior to TBS (we anticipate that it will take approximately 30 minutes to do steps 5-7).
  6. Electromyographic (EMG) electrodes will be positioned over the first dorsal interosseous (FDI) bilaterally. These are non-invasive electrodes that use an adhesive to stick to the skin.
  7. Using neuronavigation in conjunction with an atlas brain, the M1 hand strip will be localized using single pulse TMS (MagPro X100).
  8. Motor evoked potentials are measurements of muscle activation, in this case in response to TMS stimulation of the brain. We will use single pulse TMS to record the magnitude of responses. As a baseline, we will collect twenty single-pulse (120% resting motor threshold (RMT), 0.25Hz) MEPs every 5 minutes for the 15 minutes preceding TBS rTMS.
  9. We will characterize a stimulus response curve by delivering single pulse TMS at stimulation intensities ranging from 100-150% of resting motor threshold in random order.
  10. TBS rTMS will be applied to the FDI 'hotspot'. TBS consists of 2s trains every 10s. Trains are composed of 3 pulses at 50Hz, 200ms intervals, 80% RMT. Total time 190s and 600 pulses.
  11. After TBS, twenty MEPs will be acquired (single pulse, 120% RMT, 0.25Hz) every 5 minutes for the first 30 minutes, at 60 minutes, at 90 minutes, and at 16Hrs (the following morning).
  12. At the 90 minute and 16 Hrs timepoints, we will characterize stimulus response curves (MEPs at stimulus intensities ranging from 100-150% resting motor threshold presented in random order).
  13. Participants will report their perception of side effects since taking the randomized capsule (Toronto Side Effects Scale - 1 Day). Participants will be asked if they believe they received the study medication or placebo in this first phase of the crossover trial.

This study involves a crossover design, therefore after a minimum of 7 days, participants will return to the laboratory to repeat steps 4-13 with the other arm of the trial (i.e. participants who initially received the active study medication will instead receive the placebo, and the converse).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Placebo-controlled, Crossover Trial of D-cycloserine Repetitive Transcranial Magnetic Stimulation Plasticity Enhancement in the Motor System of Individuals With Major Depressive Disorder.
Actual Study Start Date : September 3, 2018
Estimated Primary Completion Date : September 3, 2019
Estimated Study Completion Date : April 1, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Cycloserine

Arm Intervention/treatment
Experimental: D-Cycloserine
Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
Drug: Cycloserine
Cycloserine 100mg

Device: Transcranial Magnetic Stimulation
Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Active Comparator: Placebo
Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
Device: Transcranial Magnetic Stimulation
Single-pulse transcranial magnetic stimulation and theta-burst stimulation

Drug: Placebo Oral Tablet
Placebo tablet matched to cycloserine tab




Primary Outcome Measures :
  1. Motor evoked potential amplitude [ Time Frame: Baseline versus 90 minutes following theta-burst stimulation. ]
    Change in the (electrical) amplitude of muscle responses to stimulation of the motor cortex will be recorded from the first dorsal interosseous muscle of the hand.


Secondary Outcome Measures :
  1. Motor evoked potential dose-response curve [ Time Frame: Baseline versus 90 minutes after theta-burst stimulation. ]
    Motor evoked potentials at stimulus intensities ranging from 100-150% resting motor threshold, presented at random order.

  2. Motor evoked potential dose-response curve [ Time Frame: Baseline versus 16 hours following theta-burst stimulation. ]
    Motor evoked potentials at stimulus intensities ranging from 100-150% resting motor threshold, presented at random order.

  3. Motor evoked potential amplitude [ Time Frame: Baseline and the evolution over 90 minutes following theta-burst stimulation. ]
    Change in the (electrical) amplitude of muscle responses to stimulation of the motor cortex will be recorded from the first dorsal interosseous muscle of the hand.


Other Outcome Measures:
  1. Safety outcomes [ Time Frame: Through study completion, on average 2 weeks. ]
    Adverse events will be tracked and recorded

  2. Side effects [ Time Frame: Baseline and 16 hours post-stimulus for both arms of the crossover study. ]
    Side effects will be tracked with the Toronto Side Effects Questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Individuals currently experiencing a major depressive episode. 1.1 As determined by the MINI-International Neuropsychiatric Interview 1.2 Moderate severity, as indicated by a Hamilton Depression Rating Scale score of ≥15.

    1.3 Be willing to remain on a stable medication regimen for 4 weeks prior the study and during the study

  2. Aged 18-60

Exclusion Criteria:

  1. Pregnancy
  2. Lactation
  3. Epilepsy
  4. Previous Stroke
  5. Current Renal Disease
  6. Current Liver Disease
  7. Current Alcohol Use Disorder
  8. Inability to refrain from alcohol use for 24 hours prior to each session and following each session.
  9. Allergy to antibiotics
  10. Use of isoniazid, ethionamide, or bupropion
  11. History of psychosis
  12. History of bipolar disorder
  13. Family history of bipolar disorder
  14. Intracranial metallic objects (dental hardware is not an exclusionary criteria)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03511599


Contacts
Layout table for location contacts
Contact: Alexander McGirr, MD MSc 403-210-6410 alexander.mcgirr@ucalgary.ca

Locations
Layout table for location information
Canada, Alberta
University of Calgary Recruiting
Calgary, Alberta, Canada, T2N1N4
Sponsors and Collaborators
University of Calgary

Layout table for additonal information
Responsible Party: University of Calgary
ClinicalTrials.gov Identifier: NCT03511599     History of Changes
Other Study ID Numbers: REB18-0604
First Posted: April 30, 2018    Key Record Dates
Last Update Posted: September 14, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: There will be no sharing of IPD.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Cycloserine
Antibiotics, Antitubercular
Anti-Bacterial Agents
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antitubercular Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action